In brief: Sofinnova Partners debuts digital medicine strategy

The strategy will be headed by partners Edward Kliphuis and Simon Turner.

Sofinnova Partners, a European life sciences venture capital firm, has launched a new investment strategy focused on digital medicine. The strategy, called Sofinnova Digital Medicine, will back entrepreneurs at the cutting edge of technology and biology.

Sofinnova, which has more than €2.5 billion under management, did not disclose how much capital it has earmarked for the new strategy, which will be led by partners Edward Kliphuis and Simon Turner.

Photo of Edward Kliphuis (L) and Simon Turner of Sofinnova Digital Medicine.
Edward Kliphuis (L) and Simon Turner, Sofinnova Digital Medicine

“We designed this strategy to help founders leverage our knowledge of highly-regulated, complex healthcare industries and build on the strengths of tech-industry approaches like rapid product iteration and swift commercialization,” Turner said in a statement.

Kliphuis added, “Simon and I bring our extensive experience investing in and developing companies at the forefront of biological innovation coupled with powerful computational techniques to help founders achieve product-market fit and scale their companies globally.”

The new effort marks the firm’s sixth and newest strategy in its multi-fund platform which spans the life sciences sector, from seed to later-stage investments in the most promising and disruptive technologies.